Experimental drug aims to rebuild immunity against rare brain infection
NCT ID NCT04781309
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a drug called NT-I7 in 12 adults with progressive multifocal leukoencephalopathy (PML), a serious brain infection that occurs in people with weakened immune systems. The goal was to see if NT-I7 could increase the number of infection-fighting white blood cells (lymphocytes) to help control the virus. Participants received up to 3 injections and were followed for 12 to 19 months with blood tests, brain scans, and spinal taps.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States